Autologous CAR-T Cell Manufacturing: Current Standing and Future Directions
A Look at What Drug Manufacturers are Likely Using to Make CAR-T Products
Supplement: MilliporeSigma Sees Opportunity in Continuous Processing
From the GEN Sounds of Science Podcast
Why CAR-T Therapies Don’t Work for Everyone Yet
Selecting the Best Type of T Cells for CAR-T May be Key to the Overall Efficacy of the Therapies
Cell-Centered: Scientists Embrace Cell-Replacement Therapy for Type 1 Diabetes
Forming Beta Cells from Stem Cells
For full access to this article login to GEN Select now.
Aseptic Filling Adjusting to New Paradigm
Complex and Sensitive Drugs Necessitate High-Tech Manufacturing Operations
- Aseptic filling—the final step before packaging parenteral small molecule and biotherapeutic drugs—represents one of the most technologically innovative and dynamic areas of downstream operations. Filling operations are changing in response to larger industry trends, explains Peter Soelkner, managing director of Vetter Pharma. “Pharmaceutical development is evolving toward highly ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.